Compare TLS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLS | FHTX |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.9M | 332.2M |
| IPO Year | 2020 | 2020 |
| Metric | TLS | FHTX |
|---|---|---|
| Price | $4.30 | $5.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.75 | ★ $11.71 |
| AVG Volume (30 Days) | ★ 715.4K | 111.3K |
| Earning Date | 01-01-0001 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.48 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $108,272,000.00 | $22,602,000.00 |
| Revenue This Year | $52.26 | $40.87 |
| Revenue Next Year | $19.65 | $11.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.83 | $2.94 |
| 52 Week High | $8.36 | $6.95 |
| Indicator | TLS | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 53.30 |
| Support Level | $3.82 | $4.44 |
| Resistance Level | $5.95 | $5.85 |
| Average True Range (ATR) | 0.26 | 0.34 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 51.65 | 73.76 |
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.